Treatment with combined dabrafenib and trametinib in BRAF(V600E)-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation.
Article Details
- CitationCopy to clipboard
Brugnara S, Sicher M, Bonandini EM, Donner D, Chierichetti F, Barbareschi M, Girardelli CR, Caffo O
Treatment with combined dabrafenib and trametinib in BRAF(V600E)-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation.
Drugs Context. 2018 Feb 15;7:212515. doi: 10.7573/dic.212515. eCollection 2018.
- PubMed ID
- 29483930 [ View in PubMed]
- Abstract
Here, we report the case of a patient, diagnosed with BRAF(V600E)-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib. After 31 months, the treatment was interrupted for patient's decision. To date October 2017, 18 months after the interruption of the treatment with the combination of dabrafenib and trametinib, follow-up Positron Emission Tomography (PET) scans are still documenting complete metabolic response.
DrugBank Data that Cites this Article
- Drugs